CSF analysis in patients with sporadic CJD and other transmissible spongiform encephalopathies

European Journal of Neurology

Volumn 14, Issue 2, 2007, Pages 121-124

  Green, A ^a   Sanchez Juan, P ^b   Ladogana, A ^c   Cuadrado Corrales, N ^d   Sanchez Valle R ^e   Mitrova E ^f   Stoeck, K ^g   Sklaviadis, T ^h   Kulczycki, J ⁱ   Heinemann, U ^j   Hess, K ^k   Slivarichova D ^f   Saiz, A ^e   Calero, M ^d   Mellina, V ^c   Knight, R ^a   Van Duijn, C M ^b   Zerr, I ^j  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f INST OF PREV AND CLINICAL MEDICINE   (Slovakia)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

ⁱ INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^j UNIVERSITY OF GÖTTINGEN   (Germany)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

Cerebrospinal fluid; Creutzfeldt Jakob disease; Transmissible spongiform encephalopathies

Indexed keywords

IMMUNOGLOBULIN G; OLIGOCLONAL BAND; PROTEIN;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CYTOLOGY; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DISEASE COURSE; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CEREBROSPINAL FLUID PROTEINS; CREUTZFELDT-JAKOB SYNDROME; EUROPE; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MONOCYTES; OLIGOCLONAL BANDS; OSMOLAR CONCENTRATION; PRION DISEASES; VARIATION (GENETICS);

EID: 33846462781     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2006.01630.x     Document Type: Article

References (18)

1. Hsich G, Kenney K, Gibbs CJ Jr, Lee KH, Harrington MG. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. New England Journal of Medicine 1996; 335: 924-930.
2. Zerr I, Bodemer M, Gefeller O, Otto M, Poser S, Wiltfang J, Windl O, Kretzschmar HA, Weber T. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Annals of Neurology 1998; 43: 32-40.
3. Poser S, Mollenhauer B, Krauß A, Zerr I, Steinhoff BJ, Schroeter A, Finkenstaedt M, Schulz-Schaeffer WJ, Kretzschmar HA, Felgenhauer K. How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain 1999; 122: 2345-2351.
4. Brown P, Gibbs CJ Jr, Rodgers-Johnson P, Asher DM, Sulima MP, Bacote A, Goldfarb LG, Gajdusek DC. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Annals of Neurology 1994; 35: 513-529.
5. Olsson JE. Brain and CSF proteins in Creutzfeldt-Jakob disease. European Neurology 1980; 19: 85-90.
6. Galvez S, Farcas A, Monari M. Cerebrospinal fluid and serum immunoglobulins and C3 in Creutzfeldt-Jakob disease. Neurology 1979; 29: 1610-1612.
7. Jones HR Jr, Hedley-Whyte ET, Freidberg SR, Baker RA. Ataxic Creutzfeldt-Jakob disease: diagnostic techniques and neuropathologic observations in early disease. Neurology 1985; 35: 254-257.
8. Signorino M, Giovagnoli AR, Sirocchi G, Censori B. Unusual findings in Creutzfeldt-Jakob disease. Case report. Italian Journal of Neurological Sciences 1988; 9: 279-282.
9. Jacobi C, Arlt S, Reiber H, Westner I, Kretzschmar HA, Poser S, Zerr I. Immunoglobulins and virus-specific antibodies in patients with Creutzfeldt-Jakob disease. Acta Neurologica Scandinavica 2005; 111: 185-190.
10. Budka H, Aguzzi A, Brown P, Brucher JM, Bugiani O, Gullotta F, Haltia M, Hauw JJ, Ironside JW, Jellinger K. Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathology, 1995; 5: 459-466.
11. Ironside JW, Sutherland K, Bell JE, McCardle L, Barrie C, Estebeiro K, Zeidler M, Will RG. A new variant of Creutzfeldt-Jakob disease: neuropathological and clinical features. Cold Spring Harbor Symposia on Quantitative Biology 1996; 61: 523-530.
12. Conly JM, Ronald AR. Cerebrospinal fluid as a diagnostic body fluid. American Journal of Medicine 1983; 75: 102-108.
13. Lott JA, Warren P. Estimation of reference intervals for total protein in cerebrospinal fluid. Clinical Chemistry 1989; 35: 1766-1770.
14. Blennow K, Fredman P, Wallin A, Gottfries CG, Karlsson I, Langstrom G, Skoog I, Svennerholm L, Wikkelso C. Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. European Neurology 1993; 33: 129-133.
15. Kleine TO, Hackler R, Zofel P. Age-related alterations of the blood-brain-barrier (bbb) permeability to protein molecules of different size. Zeitschrift fr Gerontologie 1993; 26: 256-259.
16. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clinica Chimica Acta 2001; 310: 173-186.
17. Nau R, Emrich D, Prange HW. Inverse correlation between disappearance of intrathecally injected 111In-DTPA from CSF with CSF protein content and CSF-to-serum albumin ratio. Journal of the Neurological Sciences 1993; 115: 102-104.
18. Janssen JC, Godbolt AK, Ioannidis P, Thompson EJ, Rossor MN. The prevalence of oligoclonal bands in the CSF of patients with primary neurodegenerative dementia. Journal of Neurology 2004; 251: 184-188.